General Information of the Compound
Compound ID
CP0013049
Compound Name
CARFILZOMIB
    Show/Hide
Synonyms
(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
72X6E3J5AR
868540-17-4
CHEBI:65347
CHEMBL451887
Carfilzomib
Carfilzomib (PR-171)
DSSTox_CID_28616
DSSTox_GSID_48690
DSSTox_RID_82886
Kyprolis
N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
NCGC00249613-01
PR-171
UNII-72X6E3J5AR
    Show/Hide
Structure
Formula
C40H57N5O7
Molecular Weight
719.924
Canonical SMILES
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
    Show/Hide
InChI
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
    Show/Hide
InChIKey
BLMPQMFVWMYDKT-NZTKNTHTSA-N
CAS
868540-17-4
Physicochemical Property
logP
2.5835
Rotatable Bonds
20
Heavy Atom Count
52
Polar Areas
158.47
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
8
Complexity
52

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 11556711
SID: 16658822
ChEMBL ID
CHEMBL451887
DrugBank ID
DB08889
Table of Molecular Bioactivities Related to the Compound
Cell Viability or Cytotoxicity Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000596 U266B1 Homo sapiens (Human)  1
1
IC50 = 35.7 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( Carfilzomib )
Drug Name Carfilzomib
Company Onyx Pharmaceuticals
Indication
Multiple myeloma
Approved
Small-cell lung cancer
Phase 1/2